Special Issue "Myeloid-Derived Suppressor Cells (MDSCs) in Haematology"
Deadline for manuscript submissions: 10 July 2022.
Interests: hematology; chronic neutropenia; bone marrow failure syndromes; myeloid derived suppressor cells; mesenchymal stem cells; umbilical cord blood; precision medicine
It is my honor to serve as the Guest Editor of the Special Issue “Myeloid-Derived Suppressor Cells (MDSCs) in Haematology” of the Journal of Clinical Medicine, and I would like to invite you to submit a relevant review and/or paper with new data from your research in the field. This issue will serve as a great opportunity to highlight the role of MDSCs in the pathophysiology of immune-mediated and malignant haematologic diseases and how research in the field may advance the clinical practice, particularly in the context of precision medicine.
MDSCs are immature myeloid cells with immunomodulating properties, mainly acting by suppressing T-cell responses. Most experimental and clinical studies concerning MDSCs have been focused on solid tumors, as these cells contribute to malignant cell expansion, local angiogenesis, and drug resistance. In recent years, however, the implication of MDSCs in the immune dysregulation associated with haematologic malignancies, immune-mediated cytopenias, and allogeneic haemopoietic stem cell transplantation has been documented; thus, the potential role of these cells as biomarkers and therapeutic targets has started to attract a particular interest in haematology. There is already evidence that MDSCs display altered frequency and/or functionality and could be targeted in myelodysplastic syndromes, lymphomas, myeloproliferative neoplasms, leukemia, multiple myeloma, immune mediated cytopenias, and graft-versus-host disease. The better understanding of the quantitative/functional properties of MDSCs and the mechanisms of their crosstalk with other regulatory (e.g., T-cells, natural killer cells, mesenchymal stem cells) and malignant cells in haematologic diseases may facilitate the development of novel therapeutic strategies (i.e., blockage of development, differentiation, depletion, and deactivation of MDSCs) and the recognition of novel biomarkers for personalized treatment approaches. Thus, the issue aims to cover this broad spectrum.
I look forward to receiving your submissions.
Prof. Dr. Helen A. Papadaki
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All papers will be peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Journal of Clinical Medicine is an international peer-reviewed open access semimonthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2400 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
- Myeloid-derived suppressor cells (MDSCs)
- Hematologic malignancies
- Immune-mediated cytopenias
- Graft-versus-host disease
- Therapeutic target
- Precision medicine
- Molecular pathways
- Bone marrow microenvironment
The below list represents only planned manuscripts. Some of these manuscripts have not been received by the Editorial Office yet. Papers submitted to MDPI journals are subject to peer-review.
1. New perspectives on Myeloid-Derived Suppressor Cells (MDSCs) and their emerging role in Haematology
(Abstract: Human Myeloid-Derived Suppressor Cells (MDSCs) are immature myeloid cells, characterized as CD11b+CD33+HLA-DR–/low cells that have immuno-modulating properties. They display altered frequency and functionality and may serve as promising biomarkers and targets for novel therapeutic strategies in several conditions, involving immune-mediated and malignant haematologic diseases. However, there are still difficulties in defining cell-surface markers that uniquely identify them and the functional assays are demanding. This review will try to present the current literature in a clinical point of view and trigger future investigation by serving as a guide to the clinical haematologist as well as the researcher in the field of experimental haematology.)
2. Myeloid-derived Suppressor Cell (MDSC) subsets in the Umbilical Blood Cord (UBC)
(Abstract: Myeloid-derived suppressor cells (MDSCs) are a heterogeneous population of myeloid cells that suppresses immune responses in cancer, infection and trauma, associated with poor prognosis. However, they may play a positive role in allogeneic haematopoietic stem cell transplantation inhibiting Graft-versus-Host Disease. Moreover, they are beneficial during pregnancy, as increased numbers of MDSCs, and especially granulocytic MDSCs, are crucial in immunological tolerance between mother and fetus and in the fetus growth process. Thus, human umbilical cord blood is a source rich in MDSCs. Several pregnancy complications are due to their dysregulation. The current review summarizes their roles and applications in the umbilical cord blood.)
3. Myelodysplastic Syndromes
4. Myeloproliferative Neoplasms
5. Mesenchymal Stromal Cells and Myeloid-derived suppressor cells interaction: an immunoregulatory partnership in hematologic diseases?
(Abstract: Mesenchymal stromal cells (MSCs) and myeloid-derived suppressor cells (MDSC) display immunoregulatory properties by controlling the innate and adaptive immune system that may induce a tolerant and supportive microenvironment for cancer development. So far, the interaction of MSC and MDSC into the cancer microenvironment remains a subject to be elucidated and understood. In this review, we will analyse the mutual contribution of both MSC and MDSC on the production of a tolerant cancer microenvironment, including the immunosuppressive similarities with main emphasis on haematologic diseases and their potential use in combined therapeutic strategies.)
6. Arginine deprivation can predict clinical outcome in Hodgkin Lymphoma
7. Graft-versus-Host Disease
8. MDSCs role in T-cell Lymphomas
9. Resistance to immune checkpoint inhibitors secondary to myeloid-derived suppressor cells: a new therapeutic targeting of haematologic diseases
10. MDSC in mice and men: mechanisms of immunosuppression
(Abstract: In this review, we will compare the latest insights into the immunosuppressive mechanisms murine and human myeloid-derived suppressor cells (MDSC) employ. Studying MDSC immunosuppression is hampered by their rarity, short life-spans, heterogeneity and poor viability after freezing. In mouse models, genetic manipulations can pinpoint the effect of particular enzymes or cytokines. In contrast, human studies principally rely on samples obtained from patient blood and are limited to simpler suppression assays, e.g. T cell proliferation. Therefore, some well-documented immunosuppressive mechanisms reported in mice, e.g. via immune checkpoint inhibitors, remain to be confirmed directly in human MDSC. Future studies will apply genomics and proteomics to identify MDSC-specific markers or mechanisms shared in mice and humans. These approaches could elucidate the heterogeneity and functional differences these highly plastic cells adopt in particular microenvironments.)